NLS Pharmaceutics AG (NASDAQ:NLSP – Get Rating) shares shot up 6.2% during mid-day trading on Wednesday . The stock traded as high as $1.07 and last traded at $1.03. 86,040 shares changed hands during mid-day trading, an increase of 39% from the average session volume of 61,943 shares. The stock had previously closed at $0.97.
NLS Pharmaceutics Stock Performance
The business has a 50-day simple moving average of $1.18 and a two-hundred day simple moving average of $1.31.
Institutional Trading of NLS Pharmaceutics
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Susquehanna International Group LLP bought a new position in NLS Pharmaceutics in the 1st quarter valued at approximately $35,000. Renaissance Technologies LLC grew its holdings in NLS Pharmaceutics by 58.9% in the first quarter. Renaissance Technologies LLC now owns 32,100 shares of the company’s stock worth $49,000 after purchasing an additional 11,900 shares during the period. Finally, Affinity Asset Advisors LLC acquired a new position in shares of NLS Pharmaceutics during the first quarter valued at about $520,000.
About NLS Pharmaceutics
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).
See Also
- Get a free research report on NLS Pharmaceutics from StockNews.com
- Smartsheet Investors’ Hasty Exit Can Be Your Gain
- Agilent Technologies Stock: Ready to Rise off the Floor
- Oilfield Services Growing Faster Than Wider Energy Sector
- La-Z-Boy Reclines To The Buy Zone As Industry Normalizes
- Five stocks we like better than NLS Pharmaceutics
Receive News & Ratings for NLS Pharmaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NLS Pharmaceutics and related companies with MarketBeat.com's FREE daily email newsletter.
